GENE CYP2C19 POLYMORPHISM G681A INFLUENCE ON THE EFFICACY OF CLOPIDOGREL IN ENDOVASCULAR TREATMENT OF ISCHEMIC HEART DISEASE COMORBID WITH TYPE 2 DIABETES
Aim. To research on the influence of polymorphism G681A gene CYP2C19 on efficacy of clopidogrel for planned endovascular treatment in stable CHD with second type diabetes.Material and methods. Totally 242 patients included, with chronic CHD, underwent planned angioplastics and stenting of coronary a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2015-10-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/318 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839576955844820992 |
|---|---|
| author | A. N. Repin T. N. Sergienko E. F. Muslimova E. F. Afanasyev |
| author_facet | A. N. Repin T. N. Sergienko E. F. Muslimova E. F. Afanasyev |
| author_sort | A. N. Repin |
| collection | DOAJ |
| description | Aim. To research on the influence of polymorphism G681A gene CYP2C19 on efficacy of clopidogrel for planned endovascular treatment in stable CHD with second type diabetes.Material and methods. Totally 242 patients included, with chronic CHD, underwent planned angioplastics and stenting of coronary arteries. Of those 79 had 2nd type DM. All patients received double antiplatelet therapy, including acetylsalicylic acid and clopidogrel. For efficacy evaluation, we performed the test of induced platelet aggregation with ADP in 2,5 and 5,0 mcM concentrations after total dose of clopidogrel 300 mg. Genotyping was done with allele-specific polymerase chain reaction with commercial panel “SNP-express” (SPC “LITECH”, Moscow).Results. In our selection, the carriers of allele A differed from homozygous GG with an increased grade of platelet aggregation in ADP stimulation, concentrations 2,5 mcM and 5,0 mcM. While selecting subgroups according to diabetes existence, the mention association was found in non-diabetic group, but not in comorbidity group (CHD and DM). In GG genotype, patients having 2 type DM showed the grade of induced platelet aggregation higher than in carriers of the same genotype without DM. At the same time, allele A carriers without DM did not differ from comorbidity selection in sense of ADP induced response of platelets.Conclusion. So, A allele carriage of G681A polymorphism of gene CYP2C19 is a risk factor for lower clopidogrel efficacy. Diabetes of second type also negatively influences the sensitivity to clopidogrel, but only in GG homozygous. |
| format | Article |
| id | doaj-art-f157d200f71f45fe91e70a8827d2da7d |
| institution | Matheson Library |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2015-10-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-f157d200f71f45fe91e70a8827d2da7d2025-08-04T13:00:12Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202015-10-01010818510.15829/1560-4071-2015-10-81-85318GENE CYP2C19 POLYMORPHISM G681A INFLUENCE ON THE EFFICACY OF CLOPIDOGREL IN ENDOVASCULAR TREATMENT OF ISCHEMIC HEART DISEASE COMORBID WITH TYPE 2 DIABETESA. N. Repin0T. N. Sergienko1E. F. Muslimova2E. F. Afanasyev3Scientific-Research Cardiology Institute, TomskScientific-Research Cardiology Institute, TomskНаучно-исследовательский институт кардиологии, ТомскScientific-Research Cardiology Institute, TomskAim. To research on the influence of polymorphism G681A gene CYP2C19 on efficacy of clopidogrel for planned endovascular treatment in stable CHD with second type diabetes.Material and methods. Totally 242 patients included, with chronic CHD, underwent planned angioplastics and stenting of coronary arteries. Of those 79 had 2nd type DM. All patients received double antiplatelet therapy, including acetylsalicylic acid and clopidogrel. For efficacy evaluation, we performed the test of induced platelet aggregation with ADP in 2,5 and 5,0 mcM concentrations after total dose of clopidogrel 300 mg. Genotyping was done with allele-specific polymerase chain reaction with commercial panel “SNP-express” (SPC “LITECH”, Moscow).Results. In our selection, the carriers of allele A differed from homozygous GG with an increased grade of platelet aggregation in ADP stimulation, concentrations 2,5 mcM and 5,0 mcM. While selecting subgroups according to diabetes existence, the mention association was found in non-diabetic group, but not in comorbidity group (CHD and DM). In GG genotype, patients having 2 type DM showed the grade of induced platelet aggregation higher than in carriers of the same genotype without DM. At the same time, allele A carriers without DM did not differ from comorbidity selection in sense of ADP induced response of platelets.Conclusion. So, A allele carriage of G681A polymorphism of gene CYP2C19 is a risk factor for lower clopidogrel efficacy. Diabetes of second type also negatively influences the sensitivity to clopidogrel, but only in GG homozygous.https://russjcardiol.elpub.ru/jour/article/view/318gene cyp2c19ischemic heart diseasecoronary stentingplatelet aggregationdiabetes mellitus 2 type |
| spellingShingle | A. N. Repin T. N. Sergienko E. F. Muslimova E. F. Afanasyev GENE CYP2C19 POLYMORPHISM G681A INFLUENCE ON THE EFFICACY OF CLOPIDOGREL IN ENDOVASCULAR TREATMENT OF ISCHEMIC HEART DISEASE COMORBID WITH TYPE 2 DIABETES Российский кардиологический журнал gene cyp2c19 ischemic heart disease coronary stenting platelet aggregation diabetes mellitus 2 type |
| title | GENE CYP2C19 POLYMORPHISM G681A INFLUENCE ON THE EFFICACY OF CLOPIDOGREL IN ENDOVASCULAR TREATMENT OF ISCHEMIC HEART DISEASE COMORBID WITH TYPE 2 DIABETES |
| title_full | GENE CYP2C19 POLYMORPHISM G681A INFLUENCE ON THE EFFICACY OF CLOPIDOGREL IN ENDOVASCULAR TREATMENT OF ISCHEMIC HEART DISEASE COMORBID WITH TYPE 2 DIABETES |
| title_fullStr | GENE CYP2C19 POLYMORPHISM G681A INFLUENCE ON THE EFFICACY OF CLOPIDOGREL IN ENDOVASCULAR TREATMENT OF ISCHEMIC HEART DISEASE COMORBID WITH TYPE 2 DIABETES |
| title_full_unstemmed | GENE CYP2C19 POLYMORPHISM G681A INFLUENCE ON THE EFFICACY OF CLOPIDOGREL IN ENDOVASCULAR TREATMENT OF ISCHEMIC HEART DISEASE COMORBID WITH TYPE 2 DIABETES |
| title_short | GENE CYP2C19 POLYMORPHISM G681A INFLUENCE ON THE EFFICACY OF CLOPIDOGREL IN ENDOVASCULAR TREATMENT OF ISCHEMIC HEART DISEASE COMORBID WITH TYPE 2 DIABETES |
| title_sort | gene cyp2c19 polymorphism g681a influence on the efficacy of clopidogrel in endovascular treatment of ischemic heart disease comorbid with type 2 diabetes |
| topic | gene cyp2c19 ischemic heart disease coronary stenting platelet aggregation diabetes mellitus 2 type |
| url | https://russjcardiol.elpub.ru/jour/article/view/318 |
| work_keys_str_mv | AT anrepin genecyp2c19polymorphismg681ainfluenceontheefficacyofclopidogrelinendovasculartreatmentofischemicheartdiseasecomorbidwithtype2diabetes AT tnsergienko genecyp2c19polymorphismg681ainfluenceontheefficacyofclopidogrelinendovasculartreatmentofischemicheartdiseasecomorbidwithtype2diabetes AT efmuslimova genecyp2c19polymorphismg681ainfluenceontheefficacyofclopidogrelinendovasculartreatmentofischemicheartdiseasecomorbidwithtype2diabetes AT efafanasyev genecyp2c19polymorphismg681ainfluenceontheefficacyofclopidogrelinendovasculartreatmentofischemicheartdiseasecomorbidwithtype2diabetes |